Ginkgo Bioworks Holdings, Inc.
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $170.2M
- Net income
- -$312.8M
- Total assets
- $1.1B
- Market cap
- $537.0M
- Operating margin
- -185.3%
- Net margin
- -183.8%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $170.2M
- Operating expenses
- $485.4M
- Operating income
- -$315.3M
- Income tax
- -$837.0K
- Net income
- -$312.8M
- EPS (basic)
- $-5.64
- EPS (diluted)
- $-5.64
Balance sheet
- Total assets
- $1.1B
- Current assets
- $471.8M
- Total liabilities
- $611.1M
- Current liabilities
- $96.0M
- Shareholders’ equity
- $508.6M
Cash flow
- Operating cash flow
- -$171.1M
- Investing cash flow
- -$240.3M
- Financing cash flow
- $17.8M
- Net cash flow
- -$393.4M
Statements via Polygon.io (SEC filings)
- Market cap
- $537.0M
- EPS (diluted)
- $-5.64
- Shares outstanding
- 66.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 19, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $312.8M in FY2025.
- Revenue declined 46% from FY2021 to FY2025.
- Trading 50% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Ginkgo Bioworks Holdings, Inc..
Write a review
News about Ginkgo Bioworks Holdings, Inc.
News & sentiment via Polygon.io
